Donald Mitchell
Keine laufenden Positionen mehr
Karriereverlauf von Donald Mitchell
Ehemalige bekannte Positionen von Donald Mitchell
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 01.01.2005 | 01.01.2008 |
| US Department of the Navy (District of Columbia) | Public Communications Contact | - | - |
| SPRING BANK PHARMACEUTICALS, INC. | Geschäftsführer | 01.03.2011 | - |
| Corporate Officer/Principal | 01.01.2008 | 01.03.2011 |
Ausbildung von Donald Mitchell
| United States Naval Academy | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Operating Officer | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Government | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
F-Star Therapeutics, Inc. (United States)
 F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
| US Department of the Navy (District of Columbia) | Government |
- Börse
- Insiders
- Donald Mitchell
- Erfahrung
